Overview
Depo-Provera is an injectable form of medroxyprogesterone acetate (MPA), a synthetic progestin, administered as a birth control shot typically given every three months. Marketed by Pfizer, it has been used by millions of women in the United States since its FDA approval in 1992.
Emerging scientific research has established a significant link between long-term use of Depo-Provera and the development of meningioma — a type of brain tumor that grows along the membranes surrounding the brain and spinal cord. While many meningiomas are classified as benign, they can cause severe neurological harm, require brain surgery, and in some cases become malignant.
If you or a loved one developed a meningioma after using Depo-Provera, you may have a legal claim against Pfizer for failure to warn about this serious risk.
The Link Between Depo-Provera and Meningioma
The connection between progestin-based hormonal therapies and meningioma has been documented in peer-reviewed scientific literature for years. A landmark 2024 study published in the British Medical Journal (BMJ) found that women who used Depo-Provera for more than one year faced a significantly elevated risk of developing intracranial meningioma — with some studies indicating the risk was more than five times higher than non-users.
Researchers believe that synthetic progestins like MPA stimulate progesterone receptors found on meningioma cells, fueling tumor growth. The risk appears to increase with the duration of use, making long-term Depo-Provera users particularly vulnerable.
Despite this emerging body of evidence, Pfizer's U.S. labeling for Depo-Provera did not include a warning about meningioma risk — even as regulators in France and other countries moved to restrict the drug's use and require updated warnings.
Symptoms of Meningioma
Meningiomas develop slowly and may not cause symptoms for years. When symptoms do appear, they can include:
- Persistent headaches, especially in the morning
- Vision problems, including blurred or double vision
- Hearing loss or ringing in the ears
- Memory loss or cognitive changes
- Seizures
- Weakness or numbness in the limbs
- Difficulty speaking or understanding language
- Changes in personality or behavior
Many patients first discover a meningioma incidentally during imaging for an unrelated condition. If you used Depo-Provera for an extended period and have been diagnosed with a meningioma, the connection may not have been disclosed to you by your physician or the manufacturer.
Pfizer's Failure to Warn
Drug manufacturers have a legal obligation to disclose known risks associated with their products. Plaintiffs in Depo-Provera litigation allege that Pfizer knew or should have known about the link between medroxyprogesterone acetate and meningioma, yet failed to include adequate warnings in U.S. prescribing information.
The contrast between Pfizer's U.S. labeling and the regulatory actions taken in other countries is central to these claims. France's drug safety agency suspended new prescriptions of high-dose progestin therapies for intracranial meningioma risk — a step the FDA has not yet taken despite the same underlying scientific evidence.
Who May Have a Claim
You may be eligible to file a Depo-Provera meningioma lawsuit if:
- You received Depo-Provera injections for one year or more
- You have been diagnosed with an intracranial meningioma
- Your diagnosis occurred during or after your use of Depo-Provera
Statute of limitations deadlines vary by state. If you believe you have a claim, it is important to consult with an attorney as soon as possible to preserve your legal rights.
Contact Triten Law
Triten Law is actively evaluating Depo-Provera meningioma claims. Our attorneys have extensive experience in pharmaceutical mass tort litigation and will provide a free, confidential case evaluation with no obligation. Contact us today to learn about your legal options.